We've found
4,483
archived clinical trials in
Influenza
We've found
4,483
archived clinical trials in
Influenza
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Updated: 3/30/2017
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Status: Enrolling
Updated: 3/30/2017
Click here to add this to my saved trials